Published in Eur J Immunol on November 01, 1995
Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood (2008) 6.81
Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun (2011) 1.49
How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules? Front Immunol (2014) 1.14
A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease. PLoS One (2012) 1.07
Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells. Proc Natl Acad Sci U S A (2000) 0.96
Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10. J Immunol (2011) 0.95
Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions. Clin Dev Immunol (2012) 0.88
The translation elongation factor eEF2 is a novel tumor‑associated antigen overexpressed in various types of cancers. Int J Oncol (2014) 0.87
A model for cancer-suppressive inflammation. Oncoimmunology (2012) 0.85
Molecular profiling of tumor-specific TH1 cells activated in vivo. Oncoimmunology (2013) 0.84
The aging immune system and its relationship with cancer. Aging health (2011) 0.79
Native IgG2a(b) is barely antigenic to major histocompatibility complex class II-restricted T cells owing to inefficient internalization by professional antigen-presenting cells. Immunology (2000) 0.77
Interleukin-1 is required for cancer eradication mediated by tumor-specific Th1 cells. Oncoimmunology (2015) 0.76
Tumor-specific CD4+ T cells eradicate myeloma cells genetically deficient in MHC class II display. Oncotarget (2016) 0.76
SH2D2A modulates T cell mediated protection to a B cell derived tumor in transgenic mice. PLoS One (2012) 0.76
Genes predisposing to autoimmunity augment constitutive major histocompatibility complex class II-associated presentation of the self-antigen IgG2a in vivo. Immunology (2000) 0.75
Limitations of bystander killing in Th1/M1 immune responses against a secreted tumor antigen. Oncoimmunology (2014) 0.75
Transcription of T cell receptor beta-chain genes is controlled by a downstream regulatory element. EMBO J (1988) 2.93
Cloned transcription factor MTF-1 activates the mouse metallothionein I promoter. EMBO J (1993) 2.30
Interferon-gamma receptor-1 gene polymorphism in tuberculosis patients from Croatia. Scand J Immunol (2003) 2.17
Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur J Immunol (1996) 1.49
Inbred and wild mice carry identical deletions in their E alpha MHC genes. EMBO J (1985) 1.33
Targeted disruption of the interferon-gamma receptor 2 gene results in severe immune defects in mice. Proc Natl Acad Sci U S A (1998) 1.27
Human catechol-O-methyltransferase: cloning and expression of the membrane-associated form. Proc Natl Acad Sci U S A (1991) 1.23
Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci U S A (1994) 1.17
Clonal deletion of specific thymocytes by an immunoglobulin idiotype. EMBO J (1993) 1.15
Human interferon-gamma receptor. Mapping of epitopes recognized by neutralizing antibodies using native and recombinant receptor proteins. J Biol Chem (1990) 1.13
A causative relationship between mutant IFNgR1 alleles and impaired cellular response to IFNgamma in a compound heterozygous child. Am J Hum Genet (1998) 1.12
Impaired differentiation of Schwann cells in transgenic mice with increased PMP22 gene dosage. J Neurosci (1996) 1.12
Interferon-gamma receptor-1 gene promoter polymorphisms (G-611A; T-56C) and susceptibility to tuberculosis. Scand J Immunol (2006) 1.11
Toll-like receptor 2 (P631H) mutant impairs membrane internalization and is a dominant negative allele. Scand J Immunol (2010) 1.04
The gene for the ligand binding chain of the human interferon gamma receptor. Immunogenetics (1997) 0.97
Liver metastasis of cancer facilitated by chemokine receptor CCR6. Scand J Immunol (2003) 0.97
Cloning of murine interferon gamma receptor cDNA: expression in human cells mediates high-affinity binding but is not sufficient to confer sensitivity to murine interferon gamma. Proc Natl Acad Sci U S A (1989) 0.96
Interferon-gamma gene (T874A and G2109A) polymorphisms are associated with microscopy-positive tuberculosis. Scand J Immunol (2006) 0.96
Weak positive selection of transgenic T cell receptor-bearing thymocytes: importance of major histocompatibility complex class II, T cell receptor and CD4 surface molecule densities. Eur J Immunol (1992) 0.93
A stimulatory monoclonal antibody detecting T cell receptor diversity among idiotype-specific, major histocompatibility complex-restricted T cell clones. Eur J Immunol (1990) 0.93
Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens. Ann Oncol (2004) 0.93
Flexibility of the T cell repertoire. Self tolerance causes a shift of T cell receptor gene usage in response to insulin. J Exp Med (1990) 0.90
The structure of the gene for the second chain of the human interferon-gamma receptor. J Biol Chem (1996) 0.89
Processing and presentation of idiotypes to MHC-restricted T cells. Int Rev Immunol (1993) 0.87
Clinical effect of buffy-coat vs. apheresis platelet concentrates in patients with severe thrombocytopenia after intensive chemotherapy. Vox Sang (2007) 0.85
IFN-gamma receptor-Ig fusion proteins. Half-life, immunogenicity, and in vivo activity. J Immunol (1992) 0.84
Deletion of idiotype (Id)-specific T cells in multiple myeloma. Acta Oncol (2000) 0.83
Interferon gamma receptor extracellular domain expressed as IgG fusion protein in Chinese hamster ovary cells. Purification, biochemical characterization, and stoichiometry of binding. J Biol Chem (1995) 0.82
Single nucleotide polymorphism in the interleukin 12B gene is associated with risk for breast cancer development. Scand J Immunol (2012) 0.81
Associations of the interleukin-1 gene locus polymorphisms with risk to hip and knee osteoarthritis: gender and subpopulation differences. Scand J Immunol (2013) 0.81
Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant (2012) 0.81
A rearranged lambda 2 light gene chain retards but does not exclude kappa and lambda 1 expression. Eur J Immunol (1991) 0.81
Polymorphisms in the interleukin-1 gene locus and chronic periodontitis in patients with atherosclerotic and aortic aneurysmal vascular diseases. Scand J Immunol (2014) 0.80
Preferential positive selection of T lymphocytes which express two different TCR alpha chains, an endogenous and a transgenic. Scand J Immunol (1995) 0.80
Qa-1 restricted gamma delta T cells can help B cells. Curr Top Microbiol Immunol (1991) 0.79
T cells with two Tcrbeta chains and reactivity to both MHC/idiotypic peptide and superantigen. Cell Immunol (1996) 0.79
T-cell receptor alpha haplotype influences V alpha epitope expression on both cortisone-resistant thymocytes and lymph node T cells. Scand J Immunol (1993) 0.78
Two distinct tumour necrosis factor receptors--members of a new cytokine receptor gene family. Oxf Surv Eukaryot Genes (1991) 0.78
The intracellular domain of the second chain of the interferon-gamma receptor is interchangeable between species. J Interferon Cytokine Res (1996) 0.77
Mouse macrophages carrying both subunits of the human interferon-gamma (IFN-gamma) receptor respond to human IFN-gamma but do not acquire full protection against viral cytopathic effect. J Biol Chem (1996) 0.77
Genomic organization and promoter analysis of the gene ifngr2 encoding the second chain of the mouse interferon-gamma receptor. Scand J Immunol (1996) 0.77
Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma. Leuk Lymphoma (2007) 0.76
Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic osteonecrosis. Ann Oncol (2011) 0.76
High-dose versus low-dose metoclopramide in the prevention of cisplatin-induced emesis. A randomized crossover study in patients with ovarian carcinoma. Cancer (1988) 0.75
Gene transfer experiments to study T-cell recognition of MHC and antigen. Behring Inst Mitt (1987) 0.75
Anti-class II antibodies, but not cytotoxic T-lymphocyte antigen 4-immunoglobulin hybrid molecules, prevent rejection of major histocompatibility complex class II-negative myeloma in T-cell receptor-transgenic mice. Scand J Immunol (2004) 0.75
Interferon-gamma receptor extracellular domain-IgG fusion protein produced in Chinese hamster ovary cells as mixture of glycoforms. J Interferon Cytokine Res (1995) 0.75
B lymphoma cells process and present their endogenous IG: implications for network theory. Adv Exp Med Biol (1988) 0.75
Molecular basis of the immune response. Nucleic Acids Symp Ser (1988) 0.75